MN-001
Phase 2Small molecule
MN-001 is one of 25 small molecule programs targeting Non-Alcoholic Fatty Liver Disease. It is currently in Phase 2.
1
Indications
4
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
31 competitors in Non-Alcoholic Fatty Liver Disease
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Avandia
Jazz PharmaceuticalsApproved
Bayer Aspirin
BayerApproved
Actigall
AbbVieApproved
Calciferol
Jazz PharmaceuticalsApproved
Uloric
TakedaApproved
Crestor
AstraZenecaApproved
Januvia
ZZydus Therapeutics Inc.
Approved
Jardiance
Boehringer IngelheimApproved
Glucophage
EMD SeronoApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Idiopathic Pulmonary Fibrosis1 trial
Interstitial Cystitis1 trial
Non-Alcoholic Fatty Liver Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MN-001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMediciNova